

In the Specification:

Please replace the last full paragraph on page 31 with the following:

Thus the example discloses a novel screening system for compounds with either agonist, neutral antagonist or inverse agonist activity at the β_2 -adrenoceptor in which compound activity results in a change in the fluorescence characteristics of cells expressing a β_2 -adrenoceptor-GFP fusion protein. The change in the fluorescence characteristics can be measured by either a change in cellular localisation using the confocal microscope, or by a change in total cellular fluorescence as measured in a 96-place fluorimeter. Using confocal microscopy as the detection system, an antagonist/inverse ligand would cause an increase in cell surface fluorescence of the CAM GPCR/GFP fusion protein while an agonist ligand ~~agonist ligands~~ would cause an increase in internalization of a ~~WR~~ WT GPCR/GFP fusion protein.